elranatamab
pfizer
['magnetismm-3', 'mmsm', 'elranatamab']
phase 2 elranatamab magnetismm-3 study update on results in 94 patients. overall response 60%. new dosing schedule of this bcma/cd3 bispecific antibody helped decrease risk of crs; additional studies ongoing. #mmsm #asco2022 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.